{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-008430","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.754201+00:00","generated_at":"2026-05-19T21:49:25.876590+00:00","sec_items":["5.02","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aclaris shareholders approve doubling authorized shares to 400M and new equity plan with 25.6M reserve","bullets":["Authorized common shares increased from 200M to 400M via Certificate of Amendment effective June 5, 2025; approved by ~96% of votes.","2025 Equity Incentive Plan approved with 25,556,247 share reserve (9M new shares plus rollover from prior plan).","Directors elected: Neal Walker (71.9M for), Andrew Schiff (71.7M for), William Humphries (56.7M for, 15.99M withheld).","Advisory vote on named executive officer compensation passed 55.5M to 16.98M; PwC ratified as auditor for FY2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-008430","json":"https://secwatch.observer/filing/0001558370-25-008430.json","markdown":"https://secwatch.observer/filing/0001558370-25-008430.md","text":"https://secwatch.observer/filing/0001558370-25-008430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837025008430/0001558370-25-008430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837025008430/acrs-20250605x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T21:49:25.876590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d5cb05491e7022b56cf3e7fcff3b9f8b7e10eb2c","claim":"Aclaris Therapeutics, Inc.: Increased authorized common stock from 200,000,000 to 400,000,000 shares (effective 2025-06-05).","evidence_excerpt":"the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 shares to 400,000,000 shares","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837025008430/0001558370-25-008430-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-06-05"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}